Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
Because of the effect in the treatment of NSCLC, the capecitabine and erlotinib may compose to a new regimen for NSCLC. Based on the preclinical observation and the confirmed clinical synergistic anti-tumor activity of combined capecitabine and erlotinib in gemzar refractory advanced pancreatic cancer (APC), the investigators previously conducted a phase II study of erlotinib in combination with capecitabine against NSCLC.
1. BACKGROUND AND RATIONALE 1.1 Background Lung cancer is the leading cause of cancer-related
mortality in the world. Non-small-cell lung cancer (NSCLC), the most common type of lung
cancer, comprises about 80% of all lung cancer cases, and five-year survival across all
stages is about 12%. More than 60% of all NSCLC patients have advanced or metastatic disease
that is not suitable for curative resection at diagnosis. Platinum-based chemotherapy remains
the cornerstone of treatment for these patients and results in a small but statistically
significant improvement in survival compared with supportive care alone.But the regimen is
also associated with moderate to severe hematological and non-hematological toxic effects in
a majority of patients.
Approximately two-thirds of patients diagnosed with non-small cell lung cancer (NSCLC) are 65
years or older, and nearly 50% are 70 years or older. And greater than 90% of elderly
patients experience a grade 3/4 toxicity when treated with a platinum-based
doublet..Moreover,a group of patients with the performance status ≥2 is intolerant
intravenous chemotherapy. Availability of an effective,less toxic therapy might help extend
potentially beneficial treatment to a greater proportion of elderly or patients whose
performance status ≥2.
1.2 Rationale 1.2.1 Capecitabine for NSCLC Capecitabine is an oral prodrug of 5-Fu.It is
absorbed through the intestine and converted to 5'-deoxy-S-fluorocytidine (5'-DFCR) by
carboxylesterase and then to 5'-deoxy-S-fluorouridine (5'-DFUR) by cytidine deaminase, both
steps taking place in the liver. Finally,it is converted to the only active metabolite, FU,
by thymidine phosphorylase(TP). This occurs in both tumor and normal tissues; however, the TP
is found at higher concentrations in some tumor tissue compared with normal healthy
tissue.The expression of this enzymes may influence the effect of the capecitabine. Han et al
examined the TP expression in tumor tissue samples from NSCLC patients who enrolled in a
previous phase II study of capecitabine/docetaxel chemotherapy and found that the patients
with high tumour cell thymidine phosphorylase expression show a better response to
capecitabine based chemotherapy .
The thymidylate synthase (TS) is an important target enzyme for antifolate drugs, such as
5-FU、UFT and capecitabine,because it catalyzes an essential step in DNA synthesis. The
predictive role of the expression of thymidylate synthase (TS) in tumors treated with
antifolate drugs has been extensively reported in NSCLC.In 2006, Nakano et al performed an
immunohistochemical study on the clinical significance of TS expression using 151 resected
non-small-cell lung cancer (NSCLC) patients postoperatively treated with UFT.They found that
the 5-year survival rate of patients with TS-negative tumours was significantly higher than
that with TS-positive tumours (P=0.0133).Miyoshi et al reported that the oral administration
of UFT after surgery might improve the survival of NSCLC patients when TS levels in tumor
tissues are low,with the 5-year survival rates of patients positive and negative for TS were
50.0 and 89.5%(p<0.001).Some research still found that TS expression was significantly higher
in squamous cell carcinoma compared with adenocarcinoma when both mRNA levels and protein
levels.
Recently,a Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus
Pemetrexed in Chemotherapy-Naïve Patients With Advanced-Stage Non-Small- Cell Lung Cancer
showed that Overall survival was statistically superior for cisplatin/ pemetrexed versus
cisplatin/gemcitabine in patients with adenocarcinoma.The result reminded us that patients
with adenocarcinoma were most likely to benefit from antifolate drugs.
In the preclinical study, we examined tumor specimens for TS and TP expression obtained from
171 Chinese NSCLC patients who were operated without any preoperative chemotherapy or
radiation at our institute. We categorized Grades 0 and 1 as negative, Grades 2 and 3 as
positive for both enzymes. As for TS staining, 14.6% (n = 25) were classified as Grade 0,
28.7% (n = 49) as Grade 1, 32.7% (n = 56) as Grade 2 and 24.0% (n = 41) as Grade 3. And for
TP staining, 12.3% (n = 21) were classified as Grade 0, 17.0% (n = 29) as Grade 1, 13.5% (n =
23) as Grade 2 and 57.3% (n =98) as Grade 3. Although the anti-tumor activity of capecitabine
has not been well evaluated in NSCLC, the relatively high expression of TP (70.8%) and low
expression TS (43.3%) in NSCLC provided a rationale for the use of capecitabine in patients
with this tumor.
1.2.2 Erlotinib for NSCLC Erlotinib is a novel small molecule inhibitor of the EGFR tyrosine
kinase (TK). It has been approved as monotherapy for the treatment of patients with advanced
NSCLC who have progressed following first- and second-line chemotherapy.It is fairly well
tolerated and the salient adverse effects are mild to moderate skin rash and diarrhea. And
the further study showed that adenocarcinoma histology predicted the better survival.
Recently a trial of erlotinib as first-line therapy in elderly patients has been reported by
investigators at the Dana-Farber Cancer Center. In 76 patients over the age of 70, the vast
majority with adenocarcinoma histology, the response rate was 12% and a median survival was
11 months.
1.2.3 The synergistic interaction of erlotinib and capecitabine in NSCLC. Giovannetti et al
reported that erlotinib significantly reduced TS expression and activity, possibly via E2F-1
reduction, as detected by RT-PCR and western blot, and the combination decreased TS in situ
activity in NSCLC cells. Furthermore, Van SS. et al found TS inhibitor (5-FU) increases EGFR
phosphorylation which potentially favors EGFR-TKIs activity.Thus, erlotinib and capecitabine
may have a strong synergism in NSCLC.
Because of the effect in the treatment of NSCLC, the capecitabine and erlotinib may compose
to a new regimen for NSCLC. Based on the preclinical observation and the confirmed clinical
synergistic anti-tumor activity of combined capecitabine and erlotinib in gemzar refractory
APC, we previously conducted a phase II study of erlotinib in combination with capecitabine
against NSCLC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |